Category: Pharmaceutical Science

Pomegranate Juice vs. Grapefruit: Do You Need to Worry About Drug Interactions?
Jul, 13 2026

Pomegranate Juice vs. Grapefruit: Do You Need to Worry About Drug Interactions?

Does pomegranate juice interact with medications like grapefruit juice? Recent clinical trials show it is generally safe for most drugs, unlike grapefruit. Learn the facts about CYP3A4, lab vs. human data, and when to be cautious.

NTI Drug List: Common Medications, Risks, and Monitoring Guide
Jul, 8 2026

NTI Drug List: Common Medications, Risks, and Monitoring Guide

Learn about Narrow Therapeutic Index (NTI) drugs, including common medications like warfarin and lithium, why they require strict monitoring, and how to manage generic substitution risks safely.

How to Compare Dissolution Profiles: A Practical Guide for Generics vs. Brand Drugs
Jul, 3 2026

How to Compare Dissolution Profiles: A Practical Guide for Generics vs. Brand Drugs

Learn how to compare dissolution profiles for generic vs. brand drugs using f2 factors, bootstrap methods, and regulatory standards. A practical guide for pharmaceutical professionals.

FDA Warning Letters: How to Handle Manufacturing Violations and CGMP Fines
Jun, 8 2026

FDA Warning Letters: How to Handle Manufacturing Violations and CGMP Fines

Learn how to handle FDA warning letters for manufacturing violations. We break down CGMP compliance, common causes like data integrity failures, and step-by-step strategies for effective remediation.

Rare Adverse Events with Generics: When and How to Report Side Effects
May, 27 2026

Rare Adverse Events with Generics: When and How to Report Side Effects

Learn when and how to report rare adverse events from generic medications. Understand FDA MedWatch protocols, seriousness criteria, and why your report matters for drug safety.

Annual Savings from FDA Generic Approvals: Year-by-Year Breakdown
May, 24 2026

Annual Savings from FDA Generic Approvals: Year-by-Year Breakdown

Explore the year-by-year breakdown of annual savings from FDA generic drug approvals. Discover how new entries cut costs by 70%, totaling billions in economic relief.

Biosimilar Medications: Safety, Efficacy, and Real-World Evidence Explained
May, 11 2026

Biosimilar Medications: Safety, Efficacy, and Real-World Evidence Explained

Explore the safety and efficacy of biosimilar medications. We break down the science, real-world data, and cost benefits to help you understand if switching to a biosimilar is right for you.

NTI Generics Explained: Global Regulatory Approaches and Bioequivalence Standards
May, 4 2026

NTI Generics Explained: Global Regulatory Approaches and Bioequivalence Standards

Explore how global regulators like the FDA and EMA handle NTI generics. Learn about stricter bioequivalence standards, regional differences, and the challenges facing prescribers and manufacturers in 2026.

Gastrointestinal Combination Products: Generic Availability and Alternatives
May, 3 2026

Gastrointestinal Combination Products: Generic Availability and Alternatives

Explore the landscape of gastrointestinal combination products, including generic availability, patent expirations, and cost-saving alternatives. Learn how to navigate insurance authorizations and choose between branded combos and separate generics for better GI care.

Managing Opioid Constipation with PAMORAs: A Complete Guide
Apr, 26 2026

Managing Opioid Constipation with PAMORAs: A Complete Guide

Learn how PAMORAs like methylnaltrexone and naloxegol treat opioid-induced constipation by blocking gut receptors without affecting pain relief.

The Evolution of Generic Drugs in the US: From 1820 to Today
Apr, 20 2026

The Evolution of Generic Drugs in the US: From 1820 to Today

Discover the fascinating history of generic drugs in the US, from early standardization and the Hatch-Waxman Act to the modern era of biosimilars.

Modernizing Bioequivalence Testing: New Technologies and Regulatory Shifts
Apr, 8 2026

Modernizing Bioequivalence Testing: New Technologies and Regulatory Shifts

Explore the latest advances in bioequivalence testing, from AI tools like BEAM to virtual modeling and ICH M10 standards, reducing drug development timelines.